小儿过敏性紫癜治疗中给予西咪替丁与双嘧达莫片联合治疗的临床疗效及安全性分析  

Clinical Efficacy and Safety Analysis of Cimetidine Combined with Dipyridamole Tablets in the Treatment of Children with Allergic Purpura

作　　者：孙玲 SUN Ling(Department of Pediatrics,Fengxian Hospital of Traditional Chinese Medicine,Fengxian,Jiangsu Province,221700 China)

机构地区：[1]丰县中医医院儿科,江苏丰县221700

出　　处：《系统医学》2022年第5期148-151,共4页Systems Medicine

摘　　要：目的 分析予以小儿过敏性紫癜患儿西咪替丁与双嘧达莫片联合治疗的临床效果。方法 选择2017年1月—2020年12月在该院接受治疗的62例过敏性紫癜患儿为研究对象,依据随机数字表法均分为两组,予以西咪替丁治疗的31例患儿纳入对照组,予以西咪替丁与双嘧达莫片联合治疗的31例患儿纳入观察组。对比不同治疗方案下两组患儿的治疗效果、症状改善时间、血清免疫指标水平及不良反应发生率。结果 观察组患儿治疗有效率(96.77%),与对照组(74.19%)相比较高,差异有统计学意义(χ^(2)=4.679,P<0.05)。观察组各症状(腹痛、紫癜、关节肿痛、皮疹)改善时间分别为(4.20±0.85)、(8.23±2.47)、(3.14±1.27)、(11.59±1.24)d,与对照组的(6.85±1.46)、(12.25±3.77)、(6.23±1.44)、(15.42±2.04)d相比较均较短,差异有统计学意义(t=8.734、4.966、8.178、8.932,P <0.05)。治疗后,观察组IgA (2.36±0.09)g/L、IgM (1.35±0.36)g/L、补体C3 (1.28±0.12)g/L、CRP(6.59±0.57)mg/L,均低于对照组的(3.16±0.10)g/L、(3.82±0.67)g/L、(2.47±0.13)g/L、(7.25±0.40)mg/L,差异有统计学意义(t=33.108、18.081、37.450、5.277,P<0.05)。两组不良反应发生率分别为9.68%、6.45%,差异无统计学意义(χ^(2)=0.000,P>0.05)。结论 予以小儿过敏性紫癜患儿西咪替丁与双嘧达莫片联合治疗效果显著,可有效改善患儿病症,改善其免疫力,安全性较高。Objective To analyze the clinical effect of combined treatment of cimetidine and dipyridamole in children with allergic purpura.Methods A total of 62 children with allergic purpura who were treated in the hospital from January 2017 to December 2020 were selected as the research objects,and they were divided into two groups according to the random number table method.31 children treated with cimetidine were included in the control group,and 31 children treated with cimetidine combined with dipyridamole were included in the observation group.The treatment effect,symptom improvement time,serum immune index levels and incidence of adverse reactions were compared between the two groups under different treatment regimens.Results The effective rate of treatment in the observation group(96.77%) was higher than that in the control group(74.19%),the difference was statistically significant(χ^(2)=4.679,P<0.05).The improvement time of each symptom(abdominal pain,purpura,joint swelling and pain,rash) in the observation group was(4.20 ±0.85)d,(8.23 ±2.47)d,(3.14 ±1.27)d,(11.59 ±1.24)d,respectively,compared with the control group(6.85±1.46)d,(12.25±3.77)d,(6.23±1.44)d,(15.42±2.04)d were shorter,the difference was statistically significant(t=8.734,4.966,8.178,8.932,P<0.05).After treatment,the IgA(2.36±0.09) g/L,IgM(1.35±0.36) g/L,complement C3(1.28±0.12) g/L,and CRP(6.59±0.57) mg/L in the observation group all were lower than the control group(3.16±0.10) g/L,(3.82±0.67) g/L,(2.47±0.13) g/L,(7.25±0.40) mg/L,the difference was statistically significant(t=33.108,18.081,37.450,5.277,P<0.05).The incidence of adverse reactions in the two groups was9.68% and 6.45%,respectively,the difference was not statistically significant(χ^(2)=0.000,P>0.05).Conclusion The combined treatment of cimetidine and dipyridamole tablets in children with allergic purpura has a significant effect,effectively improves the symptoms of children,and improves their immunity,with high safety.

关 键 词：小儿过敏性紫癜 西咪替丁 双嘧达莫片 免疫指标 不良反应 

分 类 号：R725[医药卫生—儿科]